NCT03241745View on ClinicalTrials.gov

A Study of Nivolumab in Selected Uterine Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 3, 2017

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Uterine CancerEndometrial CarcinomaCarcinosarcomaLeiomyosarcomaUndifferentiated SarcomaHigh Grade Endometrial Stromal SarcomaClear Cell Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab 480 mg IV once every 4 weeks

Trial Locations (8)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

18103

Lehigh Valley Health Network, Allentown

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER